Data as of Dec 12
| +0.19 / +0.86%|
Celldex Therapeutics, Inc. is an innovative biotechnology company focused on the discovery, development and commercialization of immunotherapies. Its lead drug candidates include CDX-110, CDX-011, and CDX-1127. The company has additional clinical and preclinical programs, including CDX-1401, CDX-301and CDX-1135. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Needham, MA.
|Anthony S. Marucci||President, Chief Executive Officer & Director|
|Avery W. Catlin||CFO, Secretary, Treasurer & Senior Vice President|
|Tibor Keler||Chief Scientific Officer & Senior Vice President|
|Thomas Andrew Davis||Chief Medical Officer & Senior Vice President|
|Ronald A. Pepin||Chief Business Officer & Senior Vice President|